Chronic Myelogenous Leukemia: Approaches to Pharmacological Resistance
نویسندگان
چکیده
منابع مشابه
Chronic Myelogenous Leukemia: Approaches to Pharmacological Resistance
From 2000 some data relative to IM resistance were available. There are many mechanisms responsible of IM resistance, more often point mutations that cause the progression to blast crisis and death in few months. To circumvent them, more potent TKIs have been subsequently approved [3]. However, another problem arise: these compounds don’t work on all patients because of the different IMresistan...
متن کاملNew approaches to the treatment of chronic myelogenous leukemia.
A number of therapeutic strategies have been introduced for the management and treatment of the benign phase of CML. Eighty years ago, radiation therapy was the only available treatment and splenic ir~ radiation was continued for a period in ex~ cess of 20 years when in 1924, Minot and colleagues published the now classic paper demonstrating that, although therapy could reduce morbidity of the ...
متن کاملitor Drug Resistance in Chronic Myelogenous Leukemia
ownload pite the initial effectiveness of oncogene-directed cancer therapeutics, acquired drug resistance rethe ultimate “Achilles' heel” for long-term durable remission in cancer patients. Acquisition of drug nce is not more evident elsewhere than in the use of tyrosine kinase inhibitors, imatinib and da, for patients with chronic myelogenous leukemia. Hence, even though imatinib initially pro...
متن کاملOvercoming resistance in chronic myelogenous leukemia.
Chronic myeloid leukemia is defined by the acquired genetic mutation, t(9;22), which leads to the fusion-protein BCR-ABL. Prior to the development of imatinib mesylate (Gleevec), treatment was limited and provided only limited survival benefit. Imatinib has dramatically changed the course of the disease and has led to the significantly prolonged survival in the majority of patients. However, th...
متن کاملChronic myelogenous leukemia (CML): resistance to tyrosine kinase inhibitors.
Chronic myelogenous leukemia (CML) is attributed to the chromosomal translocation t(9;22)(q34;q11), yielding the Philadelphia (Ph) chromosome. This translocation generates a fusion gene that encodes BCR-ABL, a constitutively active protein tyrosine kinase. Signal transduction pathways stimulated by BCR-ABL kinase activity promote cell survival and proliferation while inhibiting apoptosis [1]. T...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Leukemia
سال: 2017
ISSN: 2329-6917
DOI: 10.4172/2329-6917.1000e120